209 related articles for article (PubMed ID: 32930787)
21. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T; Lau KJ; Wang J; McMahon C; Kawakami Y; Tateno T; Araki T
Front Endocrinol (Lausanne); 2021; 12():624686. PubMed ID: 33841328
[TBL] [Abstract][Full Text] [Related]
22. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
23. Clinical Efficacy of Temozolomide and Its Predictors in Aggressive Pituitary Tumors and Pituitary Carcinomas: A Systematic Review and Meta-Analysis.
Luo M; Tan Y; Chen W; Hu B; Wang Z; Zhu D; Jiao H; Duan C; Zhu Y; Wang H
Front Neurol; 2021; 12():700007. PubMed ID: 34220696
[No Abstract] [Full Text] [Related]
24. Pituitary Adenomas: From Diagnosis to Therapeutics.
Banskota S; Adamson DC
Biomedicines; 2021 Apr; 9(5):. PubMed ID: 33946142
[TBL] [Abstract][Full Text] [Related]
25. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
[TBL] [Abstract][Full Text] [Related]
26. Clinical Biology of the Pituitary Adenoma.
Melmed S; Kaiser UB; Lopes MB; Bertherat J; Syro LV; Raverot G; Reincke M; Johannsson G; Beckers A; Fleseriu M; Giustina A; Wass JAH; Ho KKY
Endocr Rev; 2022 Nov; 43(6):1003-1037. PubMed ID: 35395078
[TBL] [Abstract][Full Text] [Related]
27. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract][Full Text] [Related]
29. The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment.
Li Y; Ren X; Gao W; Cai R; Wu J; Liu T; Chen X; Jiang D; Chen C; Cheng Q; Wu A; Cheng W
CNS Neurosci Ther; 2024 May; 30(5):e14729. PubMed ID: 38738958
[TBL] [Abstract][Full Text] [Related]
30.
Qiu C; Yao Y; Hu S; Xu Y
Transl Cancer Res; 2024 Feb; 13(2):661-675. PubMed ID: 38482414
[TBL] [Abstract][Full Text] [Related]
31. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract][Full Text] [Related]
32. Nelson's Syndrome: A Narrative Review.
Torres-Ríos JA; Romero-Luna G; Meraz Soto JM; Zavala-Romero L; Aguirre Maqueda ML; Rodríguez Camacho A; Moreno Jiménez S
Cureus; 2023 May; 15(5):e39114. PubMed ID: 37332454
[TBL] [Abstract][Full Text] [Related]
33. PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling.
Liu J; Wang J; Tian W; Xu Y; Li R; Zhao K; You C; Zhu Y; Bartsch JW; Niu H; Zhang H; Shu K; Lei T
Aging (Albany NY); 2022 Aug; 14(15):6066-6080. PubMed ID: 35963638
[TBL] [Abstract][Full Text] [Related]
34. A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors.
Cui J; Shen J; Ru X; Tian Z; Duan Z; Chen G; Li M
J Oncol; 2022; 2022():4618664. PubMed ID: 35368902
[TBL] [Abstract][Full Text] [Related]
35. Editorial: Resistance to Medical Therapy in Pituitary Tumors.
Auriemma RS; Gahete MD; Gatto F
Front Endocrinol (Lausanne); 2022; 13():861230. PubMed ID: 35282458
[No Abstract] [Full Text] [Related]
36. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
Mirallas O; Filippi-Arriaga F; Hernandez Hernandez I; Aubanell A; Chaachou A; Garcia-Alvarez A; Hernando J; Martínez-Saez E; Biagetti B; Capdevila J
Front Endocrinol (Lausanne); 2021; 12():731631. PubMed ID: 34858324
[TBL] [Abstract][Full Text] [Related]
37. The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas.
Xi Z; Jones PS; Mikamoto M; Jiang X; Faje AT; Nie C; Labelle KE; Zhou Y; Miller KK; Soberman RJ; Zhang X
Front Endocrinol (Lausanne); 2021; 12():726448. PubMed ID: 34745002
[TBL] [Abstract][Full Text] [Related]
38. Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma.
Lin AL; Tabar V; Young RJ; Cohen M; Cuaron J; Yang TJ; Rosenblum M; Rudneva VA; Geer EB; Bodei L
J Endocr Soc; 2021 Oct; 5(10):bvab133. PubMed ID: 34466766
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors.
Nie D; Xue Y; Fang Q; Cheng J; Li B; Wang D; Li C; Gui S; Zhang Y; Zhao P
Dis Markers; 2021; 2021():5300381. PubMed ID: 34447484
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
